Real-World Glycemic Lowering Effectiveness of Linagliptin Among Adults with Type 2 Diabetes by Age, Renal Function, and Race.

Hoogwerf, Byron J; MacKenzie, Michele; Sealls, Whitney; Cordova, Jeanine; Gandhi, Pranav

Hoogwerf, Byron J; MacKenzie, Michele; Sealls, Whitney; Cordova, Jeanine; Gandhi, Pranav.

Afiliação

Hoogwerf BJ; Eli Lilly and Company, Indianapolis, IN, USA. byronhoogwerf@gmail.com.
MacKenzie M; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Sealls W; Eli Lilly and Company, Indianapolis, IN, USA.
Cordova J; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.
Gandhi P; Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA.

Diabetes Ther ; 11(7): 1527-1536, 2020 Jul.

Article em En | MEDLINE | ID: mdl-32462538

Palavras-chave

Effectiveness; Glycated hemoglobin; Linagliptin; Renal function; Type 2 diabetes mellitus

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Tipo de estudo: Observational_studies / Risk_factors_studies Idioma: En Revista: Diabetes Ther Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google